| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Societe de Promotion Pharmaceutique du Maghreb S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.م930.50 |
| 52 Week High | د.م1,110.00 |
| 52 Week Low | د.م921.00 |
| Beta | -0.18 |
| 11 Month Change | -0.37% |
| 3 Month Change | 0.81% |
| 1 Year Change | -4.27% |
| 33 Year Change | 2.24% |
| 5 Year Change | 9.47% |
| Change since IPO | -4.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| PRO | MA Pharmaceuticals | MA Market | |
|---|---|---|---|
| 7D | 0.9% | 3.5% | 0.4% |
| 1Y | -4.3% | 17.0% | 12.3% |
Return vs Industry: PRO underperformed the MA Pharmaceuticals industry which returned 17% over the past year.
Return vs Market: PRO underperformed the MA Market which returned 12.3% over the past year.
Price Volatility
| PRO volatility | |
|---|---|
| PRO Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in MA Market | 7.3% |
| 10% least volatile stocks in MA Market | 2.5% |
Stable Share Price: PRO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PRO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | n/a | Salameh Al Araideh | www.promopharm.co.ma |
Societe de Promotion Pharmaceutique du Maghreb S.A. produces, commercializes, imports, and exports medicines, derma-pharmaceuticals, and cosmetic products in Africa. It subcontracts medicines for national and international laboratories. The company was founded in 1947 and is headquartered in Had-Soualem, Morocco.
Societe de Promotion Pharmaceutique du Maghreb S.A. Fundamentals Summary
| PRO fundamental statistics | |
|---|---|
| Market cap | د.م930.50m |
| Earnings (TTM) | د.م56.90m |
| Revenue (TTM) | د.م805.52m |
16.4x
P/E Ratio1.2x
P/S RatioIs PRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRO income statement (TTM) | |
|---|---|
| Revenue | د.م805.52m |
| Cost of Revenue | د.م446.27m |
| Gross Profit | د.م359.24m |
| Other Expenses | د.م302.34m |
| Earnings | د.م56.90m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 56.90 |
| Gross Margin | 44.60% |
| Net Profit Margin | 7.06% |
| Debt/Equity Ratio | 27.1% |
How did PRO perform over the long term?
See historical performance and comparison